Illumina Tells Investors Cancer Samples, Not Sequencing, Are Bottleneck in Dx Initiative | GenomeWeb

By Julia Karow

This article was originally published Sept. 24.

Illumina is plowing ahead with an internal cancer-sequencing project that is part of its diagnostic initiative, but has found it difficult to procure suitable patient samples, CEO Jay Flatley said during a recent investor conference.

He also said that the company continues to be confident about Oxford Nanopore Technologies, in which it invested $18 million earlier this year, and is "pleased with" the progress of the startup.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.